ERF.PA
BuyFull HouseAI neutralEurofins Scientific SE · Healthcare · Luxembourg · $14.8B
EUR 76.52 +0.5% · close 7 Oct · scored 9 Oct
Full House: Strong business, sensible price, market agrees. The rare full house.
Read our full research report on ERF.PA (Jun 2026), freeDoes StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
Eurofins is a global leader in food, environmental, pharmaceutical and clinical testing with scale advantages in a fragmented market. It is sharpening its focus by selling its electrical testing business at a good price, and the CEO's holding vehicle has been buying shares. Offsetting this, forward estimates were cut 2.0% in the past month and the group has faced past questions about its complex related-party property arrangements and accounting.
ABOUT EUROFINS SCIENTIFIC SE
Read
Eurofins Scientific SE is a world leader in bioanalytical testing, providing an extensive portfolio of laboratory services across pharmaceuticals, food, environmental, and product testing sectors. The company's formidable competitive moat is built upon its unparalleled breadth of testing capabilities, vast global network of state-of-the-art laboratories, and stringent regulatory compliance. Eurofins continues to expand its market leadership through strategic acquisitions and innovation in complex analytical services.
FINANCIAL SUMMARY (EUR)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.7B | 6.5B | 7.0B | 7.3B | 2.8% | 7.4B | 7.5B | 7.9B | 4.3% |
| EPS (EUR) | 3.17 | 1.61 | 2.13 | 2.64 | -5.9% | 2.90 | 2.79 | 3.15 | 9.3% |
| Shares | 192.5M | 192.0M | 186.8M | 176.7M | -8.2% | 171.1M | — | — | — |
| Debt | 3.3B | 3.9B | 3.6B | 4.4B | 10.0% | 4.5B | — | — | — |
| Equity | 4.8B | 5.1B | 5.3B | 4.5B | -1.7% | — | — | — | — |
| Op CF | 1.1B | 1.0B | 1.3B | 1.4B | 7.2% | 1.5B | — | — | — |
| Inv CF | -855.9M | -681.1M | -846.5M | -1.1B | — | — | — | — | — |
| Fin CF | -311.3M | 413.6M | -1.1B | -101.6M | — | — | — | — | — |
Calmer than 78% of stocks we rank over the past year (27% a year).
How this is worked out
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ERF.PA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ERF.PA | Eurofins Scientific SE(you) | $14.8B | 80 | Buy |
| ALVO-SDB.ST | Alvotech | $2.0B | 38 | Hold |
| AUNA | Auna SA | $381M | 57 | Hold |
Peer medians: ROE 1.6% · P/E 84.3x · Gross margin 60.7%
Company Deep Dive
Read the full research report: business segments breakdown, earnings transcripts review, management credibility analysis, competitive landscape, and scenarios.